Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $15.8 million.

  • Akebia Therapeutics' Change in Accured Expenses rose 606.21% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 383.23%. This contributed to the annual value of -$12.8 million for FY2024, which is 27.50% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Change in Accured Expenses is $15.8 million, which was down 1.14% from $16.0 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Change in Accured Expenses registered a high of $30.8 million during Q3 2021, and its lowest value of -$37.2 million during Q4 2021.
  • Its 3-year average for Change in Accured Expenses is $1.1 million, with a median of $3.7 million in 2023.
  • In the last 5 years, Akebia Therapeutics' Change in Accured Expenses plummeted by 440.04% in 2023 and then skyrocketed by 2,984.20% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Change in Accured Expenses (Quarterly) stood at -$37.2 million in 2021, then skyrocketed by 55.70% to -$16.5 million in 2022, then soared by 122.55% to $3.7 million in 2023, then spiked by 31.26% to $4.9 million in 2024, then soared by 606.21% to $15.8 million in 2025.
  • Its Change in Accured Expenses was $15.8 million in Q3 2025, compared to $16.0 million in Q2 2025 and $2.8 million in Q1 2025.